BerGenBio Logo

BerGenBio

ISIN: NO0010650013 | Ticker: BGBIO | LEI: 213800TYYFXKYF3V2A23
Sector: Health CareSub-Industry: Biotechnology
Country: Norway

About BerGenBio

Company Description

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections.

AXL: a promising target to treat life-threatening diseases
The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab.

Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.

Year founded

2007

Served area

Worldwide

Headquarters

Møllendalsbakken 9, 5867 Bergen – Norway

Financial statements

Download as Excel
Line item in (nok) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 738,200,000.00 450,236,000.00 166,706,000.00
Noncurrent Assets N/A 2,332,000.00 1,191,000.00 43,000.00
Current Assets N/A 735,869,000.00 449,045,000.00 166,663,000.00
Cash and cash equivalents 253,586,000.00 721,641,000.00 436,646,000.00 150,803,000.00
Other Current Assets N/A 14,228,000.00 12,398,000.00 15,860,000.00
Equity And Liabilities N/A 738,200,000.00 450,236,000.00 166,706,000.00
Equity 219,754,000.00 670,229,000.00 384,426,000.00 88,498,000.00
Issued Capital N/A 8,726,000.00 8,846,000.00 8,866,000.00
Share Premium N/A 628,231,000.00 335,195,000.00 35,780,000.00
Additional Paidin Capital N/A 33,272,000.00 40,386,000.00 43,852,000.00
Liabilities N/A 67,971,000.00 65,810,000.00 78,208,000.00
Noncurrent Liabilities N/A 1,367,000.00 942,000.00 275,000.00
Longterm Borrowings N/A 1,367,000.00 942,000.00 N/A
Current Liabilities N/A 66,604,000.00 64,868,000.00 77,933,000.00
Current Provisions N/A 6,008,000.00 969,000.00 0.00
Trade And Other Current Payables To Trade Suppliers N/A 22,550,000.00 26,726,000.00 29,634,000.00
Other Current Liabilities N/A 38,046,000.00 37,172,000.00 48,299,000.00
Line item in (nok) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 601,000.00 774,000.00 389,000.00
Wages And Salaries 48,832,000.00 69,929,000.00 66,143,000.00
Other Employee Expense 11,346,000.00 4,116,000.00 2,546,000.00
Depreciation Expense 726,000.00 1,312,000.00 883,000.00
Other Expense By Nature 200,788,000.00 239,880,000.00 236,451,000.00
Profit Loss From Operating Activities -261,091,000.00 -314,464,000.00 -305,635,000.00
Finance Income 19,499,000.00 15,993,000.00 15,027,000.00
Finance Costs 15,437,000.00 10,894,000.00 11,514,000.00
Profit Loss Before Tax -257,029,000.00 -309,364,000.00 -302,122,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -257,029,000.00 -309,364,000.00 -302,122,000.00
Line item in (nok) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -257,029,000.00 -309,364,000.00 -302,122,000.00
Adjustments For Provisions N/A 3,934,000.00 -5,039,000.00 -969,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 710,000.00 667,000.00 3,280,000.00
Adjustments For Sharebased Payments N/A 7,412,000.00 7,113,000.00 3,466,000.00
Cash Flows From Used In Operating Activities N/A -234,290,000.00 -303,340,000.00 -288,231,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities N/A N/A N/A 299,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 67,000.00 N/A N/A
Interest Received Classified As Investing Activities N/A 3,614,000.00 3,130,000.00 2,949,000.00
Cash Flows From Used In Investing Activities N/A 3,548,000.00 3,130,000.00 3,248,000.00
Proceeds From Issuing Shares N/A 740,852,000.00 16,629,000.00 3,218,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 585,000.00 565,000.00 307,000.00
Cash Flows From Used In Financing Activities N/A 699,507,000.00 15,995,000.00 2,904,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 468,765,000.00 -284,216,000.00 -282,080,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -710,000.00 -779,000.00 -3,764,000.00
Cash and cash equivalents 253,586,000.00 721,641,000.00 436,646,000.00 150,803,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

NO0010650013

LEI

213800TYYFXKYF3V2A23

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Oslo Børs

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.